-
Elfcare to integrate health data with ChatGPT – leaves sharing to users
Healthcare company Elfcare has launched a new connector that allows users to share results from its health assessments with AI assistants. Speaking to Life Science Focus’s sister publication Medtech Magazine, co-founder Julia Elf discusses the initiative and how the company approaches questions around data protection and responsibility.
-
Disruptive sells former Guard platform – deal ‘not financially material’
What was formerly Guard Therapeutics became Disruptive Pharma following a reverse acquisition. Now, one of the remaining parts of the former Guard business is being sold as the listed company shifts its full focus to Disruptive’s formulation technology.
-
Changing jobs in the Nordics? Avoid this common mistake
It is easy to assume that working in Copenhagen, Stockholm, Oslo or Helsinki will not be all that different from working in a neighbouring Nordic country. According to career coach Tina Persson, that assumption is one of the biggest pitfalls.
-
Novo Nordisk enters billion-dollar collaboration with Orbis Medicines
Danish pharmaceutical company Novo Nordisk has entered into a strategic collaboration and licensing agreement with fellow Danish company Orbis Medicines to develop next-generation oral medicines for cardiometabolic diseases. This is stated in a press release.
-
Mölnlycke to split into two companies
The Swedish medtech company Mölnlycke plans to separate its Operating Room Solutions (ORS) and Gloves businesses into a new stand-alone company, Mölnlycke Surgical. The change is expected to be completed during 2027.
-
Lilly is sanctioned for remarks to Swedish media
Eli Lilly is being sanctioned for statements made in an interview with a Swedish newspaper, in which a yet‑to‑be‑approved obesity drug is claimed to “stand in a class of its own”.
-
Orexo CEO on settlement: “Very mixed feelings”
After more than $14m in legal fees and years of uncertainty, Orexo is closing in on a settlement with the US Department of Justice.
-
From space to the world’s first fertility app: “Physics had always been my only dream”
She was user number one. Today, more than six million women worldwide have used the fertility app Natural Cycles, which is now rapidly expanding its offering. But there was a time when particle physics was all Elina Berglund Scherwitzl could think about.
-
Sanofi Sweden: ”We will work for more clinical trials”
Sanofi Sweden may represent only a modest share of the global Sanofi group, which employs nearly 80,000 people, but it still makes a significant research impact. Sweden Country Manager Daniel Sandgren hopes that will remain the case – yet he also sees clouds on the horizon.“Sweden risks losing its strong position in clinical trials”, he says in an interview.
-
The vaccine has saved 94 million lives – but measles is spreading again
A disease we once believed belonged to the past is now resurging in both Europe and the United States. In Sweden, 24 cases of the disease have so far been reported in an ongoing outbreak linked to a music festival. In the shadow of growing skepticism and declining vaccination coverage, measles – which has claimed millions of lives throughout history – is making a comeback.
-
New FDA setback for Xspray – stock plunges
The Swedish research company Xspray Pharma has received yet another negative decision from the U.S. Food and Drug Administration (FDA), linked to the company’s Italian third‑party manufacturer.
-
LEO Pharma acquires dermatology drug for 435 million USD
LEO Pharma strengthens its dermatology portfolio by acquiring the late-stage drug candidate dersimelagon.
-
Hansa chair: “Too many boards spend far too much time looking inwards”
Following a change of chief executive and a sharper strategic focus, Hansa Biopharma is entering a decisive phase in the US market. As the company prepares for what comes next, chair Peter Nicklin is clear about his own role: to lead the board, but never dominate it.
-
Disappointment for Diamyd in Phase III – the share price plunges
Diamyd Medical’s share was sharply down on Monday following negative Phase III results. “This outcome is highly unexpected,” said the company’s CEO, Ulf Hannelius.
-
Lost in the recruitment process? How hiring really works today
As recruitment becomes increasingly automated, candidates are expected to adapt to both human and algorithmic decision-making. Career coach Tina Persson outlines why the process feels unfair – and how jobseekers can approach it more strategically.
-
Obesity dominates as future blockbusters are identified
Two drug candidates targeting obesity and diabetes stand out sharply in Clarivate’s newly selected “starting eleven” of potential future blockbusters worth watching.
-
“There’s no magic wand” – The urgent need for new treatments
One in ten women with recurrent yeast infections develops a stubborn, hard-to-treat condition for which no effective therapies currently exist. At Danderyd Hospital, researcher Cathrin Alvendal at the Women’s Clinic research unit is working to change that. This is the second instalment in Life Science Sweden’s series on fungi.
-
FDA launches investigation into gene therapy following child death
The U.S. Food and Drug Administration (FDA) has initiated a safety investigation into Takeda’s Adzynma after reports that a child has died during treatment. The incident is described as likely related to the drug.
-
How the Nobel discovery is used in drug development
Regulatory T cells keep the immune system in check, a discovery now awarded the 2025 Nobel Prize in Physiology or Medicine. Qiang Pan Hammarström explains how this finding is being applied in today’s drug development, and what challenges remain.
-
Heart Monitoring in Breast Cancer – Essential or Excessive?
Trastuzumab and related drugs have transformed breast cancer treatment and dramatically improved survival rates. But the close cardiac monitoring required during treatment can be a heavy burden for both patients and healthcare systems. Dr. Andri Papakonstantinou is working to refine how doctors identify which patients truly need intensive follow-up.
-
US Health Secretary Kennedy dismisses all vaccine experts – assembles new committee
Robert F. Kennedy Jr. has dismissed all 17 members of the CDC’s vaccine advisory panel. A new group of experts will be appointed directly by the Health Secretary, his department announced.
-
Charged with illegal pharmaceutical sales – alleged earnings of 23 million
For at least five years, two men allegedly carried out illegal sales of pharmaceuticals and supplements, amassing millions. They are now facing charges at Södertörn District Court in Huddinge, south of Stockholm.
-
Positive EMA Decision for BioArctic's New Drug Candidate
Bioarctic's drug candidate for multiple system atrophy, exidavnemab, is recommended to be classified as an orphan drug, according to the European Medicines Agency (EMA).
-
Venomaid's rapid test aims to find the right snake bite treatment
Every six seconds, someone on our planet suffers a snake bite, and each time, a race against the clock begins. What kind of snake was it, and which antivenom can help? Danish company Venomaid Diagnostics is working hard to develop solutions to a problem that claims countless lives, especially in tropical countries.
Get access to all content on Life Science Focus
No commitment or card information required
Already a subscriber? Log In
Applies to personal subscription only.
Contact us for a enterprise solution.
Advertisement
Advertisement
Advertisement
Advertisement
BREAKING